Literature DB >> 27591074

Short chain fatty acids and gut microbiota differ between patients with Parkinson's disease and age-matched controls.

Marcus M Unger1, Jörg Spiegel2, Klaus-Ulrich Dillmann2, David Grundmann3, Hannah Philippeit2, Jan Bürmann2, Klaus Faßbender2, Andreas Schwiertz4, Karl-Herbert Schäfer3.   

Abstract

BACKGROUND: Patients with Parkinson's disease (PD) frequently have gastrointestinal symptoms (e.g. constipation) and exhibit the PD-typical pathohistology in the enteric nervous system (ENS). Both, clinical symptoms and pathohistological changes in the ENS occur at early stages and can precede the motor manifestations of PD. Two recent studies reported an association between changes in gut microbiota composition and PD. We hypothesized that alterations in gut microbiota might be accompanied by altered concentrations of short chain fatty acids (SCFA), one main metabolic product of gut bacteria.
METHODS: We quantitatively analyzed SCFA concentrations (using gas chromatography) and microbiota composition (using quantitative PCR) in fecal samples of 34 PD patients and 34 age-matched controls.
RESULTS: Fecal SCFA concentrations were significantly reduced in PD patients compared to controls. The bacterial phylum Bacteroidetes and the bacterial family Prevotellaceae were reduced, Enterobacteriaceae were more abundant in fecal samples from PD patients compared to matched controls.
CONCLUSIONS: Our study confirms the recently reported association between PD and the abundance of certain gut microbiota and shows a reduction in fecal SCFA concentrations (one main metabolic product of certain gut bacteria). The reduction in SCFA might, theoretically, induce alterations in the ENS and contribute to gastrointestinal dysmotility in PD. Prospective longitudinal studies in subjects at risk for PD are required to further elucidate the causal role of gut microbiota and microbial products in the development of PD and PD-associated dysmotility.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Butyrate; Enteric nervous system; Gut microbiota; Parkinson's disease; Short chain fatty acids

Mesh:

Substances:

Year:  2016        PMID: 27591074     DOI: 10.1016/j.parkreldis.2016.08.019

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  282 in total

Review 1.  Movement disorders in 2016: Progress in Parkinson disease and other movement disorders.

Authors:  Joseph Jankovic
Journal:  Nat Rev Neurol       Date:  2017-01-13       Impact factor: 42.937

2.  Colon-delivered short-chain fatty acids attenuate the cortisol response to psychosocial stress in healthy men: a randomized, placebo-controlled trial.

Authors:  Bram Vervliet; Kristin Verbeke; Lukas Van Oudenhove; Boushra Dalile; Gabriela Bergonzelli
Journal:  Neuropsychopharmacology       Date:  2020-06-10       Impact factor: 7.853

3.  Microglia, inflammation and gut microbiota responses in a progressive monkey model of Parkinson's disease: A case series.

Authors:  Valerie Joers; Gunasingh Masilamoni; Doty Kempf; Alison R Weiss; Travis M Rotterman; Benjamin Murray; Gul Yalcin-Cakmakli; Ronald J Voll; Mark M Goodman; Leonard Howell; Jocelyne Bachevalier; Stefan J Green; Ankur Naqib; Maliha Shaikh; Phillip A Engen; Ali Keshavarzian; Christopher J Barnum; Jonathon A Nye; Yoland Smith; Malú G Tansey
Journal:  Neurobiol Dis       Date:  2020-07-24       Impact factor: 5.996

Review 4.  Microbiome, Immunomodulation, and the Neuronal System.

Authors:  Eric Marietta; Irina Horwath; Veena Taneja
Journal:  Neurotherapeutics       Date:  2018-01       Impact factor: 7.620

5.  α-Synuclein in gut endocrine cells and its implications for Parkinson's disease.

Authors:  Rashmi Chandra; Annie Hiniker; Yien-Ming Kuo; Robert L Nussbaum; Rodger A Liddle
Journal:  JCI Insight       Date:  2017-06-15

6.  Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome.

Authors:  Erin M Hill-Burns; Justine W Debelius; James T Morton; William T Wissemann; Matthew R Lewis; Zachary D Wallen; Shyamal D Peddada; Stewart A Factor; Eric Molho; Cyrus P Zabetian; Rob Knight; Haydeh Payami
Journal:  Mov Disord       Date:  2017-02-14       Impact factor: 10.338

Review 7.  Nutritional modulation of the intestinal microbiota; future opportunities for the prevention and treatment of neuroimmune and neuroinflammatory disease.

Authors:  Vincent C Lombardi; Kenny L De Meirleir; Krishnamurthy Subramanian; Sam M Nourani; Ruben K Dagda; Shannon L Delaney; András Palotás
Journal:  J Nutr Biochem       Date:  2018-04-19       Impact factor: 6.048

8.  Neuroprotection of Fasting Mimicking Diet on MPTP-Induced Parkinson's Disease Mice via Gut Microbiota and Metabolites.

Authors:  Zhi-Lan Zhou; Xue-Bing Jia; Meng-Fei Sun; Ying-Li Zhu; Chen-Meng Qiao; Bo-Ping Zhang; Li-Ping Zhao; Qin Yang; Chun Cui; Xue Chen; Yan-Qin Shen
Journal:  Neurotherapeutics       Date:  2019-07       Impact factor: 7.620

Review 9.  The Central Nervous System and the Gut Microbiome.

Authors:  Gil Sharon; Timothy R Sampson; Daniel H Geschwind; Sarkis K Mazmanian
Journal:  Cell       Date:  2016-11-03       Impact factor: 41.582

Review 10.  Defining Dysbiosis in Disorders of Movement and Motivation.

Authors:  Christopher T Fields; Timothy R Sampson; Annadora J Bruce-Keller; Drew D Kiraly; Elaine Y Hsiao; Geert J de Vries
Journal:  J Neurosci       Date:  2018-10-31       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.